Business Wire

Cognite Appoints Girish Rishi as CEO

Share

Cognite, a global leader in industrial software, today announced that Girish Rishi, a global enterprise software and technology leader, has been appointed CEO, effective April 4, 2022. Cognite co-founder and outgoing CEO, Dr. John Markus Lervik, will continue to be actively involved in the company as Chief Strategy & Development Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005504/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Girish Rishi, CEO of Cognite, and Dr. John Markus Lervik, Chief Strategy & Development Officer at Cognite. Source: Cognite

“John Markus has built Cognite into Norway's first unicorn and established a leading position in the transforming industrial software market,” said Øyvind Eriksen, chair of the Cognite Board of Directors. “Today we are excited to have Girish Rishi join the company, who brings with him proven software and technology experience. Girish is a world-class talent and will partner with John Markus and the Cognite team to scale the company globally.”

“As the energy and industrial sectors pivot to macro realities, Cognite's software platform will enable companies to deliver on sustainability goals and leverage operational efficiencies,” said Girish Rishi, incoming CEO. “I look forward to partnering with John Markus, who has an impressive track record of building transformative software companies, as we serve our growing customer and partner base.”

“At Cognite, we started out with a vision of an industrial world powered by data, reinventing the way asset-intensive domains are run. Today we have customers across the world, as well as application partners and integrators leveraging our software, Cognite Data Fusion,” said Cognite co-founder and Chief Strategy & Development Officer, Dr. John Markus Lervik. “I couldn’t be prouder of what we’ve all achieved so far, and I’m even more excited as we envision the future, now in close partnership with Girish.”

Both Lervik and Rishi see this leadership addition as an opportunity to further strengthen Cognite’s growth journey and its software products to build autonomous, high-tech, data-driven industries. With Rishi as CEO, Lervik will focus on high-impact business opportunities for Cognite. He will also take a leading position within other software investments in Aker ASA, Cognite’s majority shareholder, which will build out an industrial software ecosystem around Cognite.

Girish Rishi joins Cognite after serving as CEO of Blue Yonder (formerly known as JDA Software), a US-based global software company that provides supply chain management solutions.

Prior to his CEO position at Blue Yonder, Rishi held executive leadership positions in general management, product development, and go-to-market for Tyco, Motorola, and Symbol Technologies.

The appointment of Rishi follows an extensive search, led by Lervik and Cognite’s Board of Directors, to add new leadership that will further accelerate Cognite’s growth and solidify the company’s position as a leader in the industrial software market.

About Cognite

Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability.

Visit us at www.cognite.com and follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michelle Holford
Global PR Lead, Cognite
+47 482 90 454 (NO)
+1 (512) 744-3420 (US)
michelle.holford@cognite.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists23.4.2024 13:00:00 CEST | Press release

Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423725958/en/ “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “EP262 and EP547 are complementary additions to our portfolio, prov

REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements23.4.2024 12:43:00 CEST | Press release

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share. The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024). 2023 Financial Statement The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022. Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022). EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022). The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million. The Shareholders’ Meeting also adopted the following reso

Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor23.4.2024 12:30:00 CEST | Press release

Intelligent power management company Eaton today announced it has been chosen to supply an electromechanical actuation system (EMAS) that can deliver an early intake valve closing (EIVC) to the China-based automaker Great Wall for use in a line of hybrid-electric vehicles (HEV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423118914/en/ Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator. (Photo: Business Wire) “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group. “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.” The Eaton EMAS is a di

Rasa Recognized as a Representative Vendor in Gartner ® Market Guide for Conversational AI Solutions23.4.2024 12:03:00 CEST | Press release

Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of AI-driven communication and its commitment to delivering innovative solutions that enhance business interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423570629/en/ Rasa has been recognized as a Representative Vendor in the Gartner Market Guide for Conversational AI Solutions, highlighting its role in transforming business operations through AI-driven conversations. This acknowledgment underscores the importance of evaluating the Conversational AI market to enhance customer interactions, achieve cost efficiencies, and elevate customer service. (Graphic: Business Wire) Melissa Gordon, CEO of Rasa, shares her thoughts: “We think recognition from Gartner® validates our

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer23.4.2024 12:00:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the

HiddenA line styled icon from Orion Icon Library.Eye